AKTS Company Profile and Key Details

Q: Who are the executives of AKTS?

Mr. Andrew WrightGen. Counsel & Corporation Sec.Mr. Jeffrey B. ShealyFounder, Pres, Chief Executive Officer & DirectorMr. Kenneth E. BollerChief Financial Officer & Corporation ControllerMr. Kamran CheemaChief Product OfficerMr. David M. AicheleExecutive Vice President of Bus. Devel.Ms. Mary WintersExecutive Vice President of Fab & Corporation OperationsMr. Thomas Andrew SepenzisVice President of Corporation Devel. & IR

NASDAQ : AKTS

Aktis Oncology

$23.17

-0.13-0.56%

At Close 4:00 PM

61.81

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Aktis Oncology, Inc. (AKTS) stock declined over -0.56%, trading at $23.17 on NASDAQ, down from the previous close of $23.30. The stock opened at $23.36, fluctuating between $22.79 and $23.71 in the recent session.

Stock Snapshot

23.3

Prev. Close

1.24B

Market Cap

22.79

Day Low

-1.25

P/E Ratio

-18.57

EPS (TTM)

-0.72

Cash Flow per Share

23.36

Open

53.4M

Number of Shares

23.705

Day High

97.52%

Free Float in %

0.74

Book Value

330.07K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Sep 14, 2026	23.36	23.71	22.79	23.17	330.07K
Sep 11, 2026	24.36	24.54	23.25	23.30	228.58K
Sep 10, 2026	23.80	24.36	23.57	23.94	263.33K
Sep 09, 2026	25.57	26.00	24.03	24.06	377.36K
Sep 08, 2026	26.99	26.99	24.23	25.02	567.23K
Sep 04, 2026	26.18	27.20	26.18	27.05	159.25K
Sep 03, 2026	27.29	27.66	26.08	26.65	152.4K
Sep 02, 2026	26.12	27.03	25.71	26.92	253.4K
Sep 01, 2026	25.80	26.20	25.12	25.99	231.51K
Aug 31, 2026	25.57	26.05	25.14	25.91	213.61K
Aug 28, 2026	25.96	26.80	25.52	25.78	314.64K
Aug 27, 2026	26.32	27.18	26.15	26.18	210.62K
Aug 26, 2026	26.60	26.96	25.96	26.51	257.59K
Aug 25, 2026	26.30	26.89	25.47	26.69	601.23K
Aug 24, 2026	24.15	26.31	22.96	25.98	774.24K
Aug 21, 2026	24.33	25.00	24.00	24.07	226.26K
Aug 20, 2026	24.75	24.75	23.44	24.00	253.62K
Aug 19, 2026	26.28	26.28	24.42	25.02	216.54K
Aug 18, 2026	24.55	25.06	24.28	25.00	183.98K
Aug 17, 2026	24.89	24.89	24.11	24.72	163.13K

Contact Details

Boston, MA 02210

United States

https://www.aktisoncology.com 617 461 4023

About Company

Aktis Oncology, Inc. is a clinical-stage biotechnology firm dedicated to advancing targeted radiopharmaceutical therapies for cancer treatment. Their core innovation lies in a proprietary miniprotein radioconjugate platform, which enables the discovery and development of potent radiopharmaceutical therapies designed to precisely deliver tumor-killing radioisotopes. Among their pipeline candidates is Nectin-4, a miniprotein radioconjugate specifically engineered to treat locally advanced or metastatic urothelial cancer. Key programs also include AKY-1189, a radioconjugate engineered to target Nectin-4 expressing tumors across various indications such as metastatic urothelial cancer, breast cancer, non-small cell lung cancer (NSCLC), colorectal cancer, and cervical cancer. Another significant therapy, AKY-2519, is under development to deliver radioisotopes to B7-H3 (CD276) expressing tumors, addressing prostate cancer, lung cancer, and other solid tumor types. Originally incorporated as HotKnot Therapeutics, Inc., the company officially rebranded to Aktis Oncology, Inc. in April 2020. Founded in 2020, Aktis Oncology maintains its headquarters in Boston, Massachusetts.

Stock Peers

ARGX

6.15+0.62%

argenx SE$990.54 REGN

12.25+1.57%

Regeneron Pharmaceuticals, Inc.$793.74 MDGL

5.57+1.04%

Madrigal Pharmaceuticals, Inc.$540.06 VRTX

4.07+0.79%

Vertex Pharmaceuticals Incorporated$519.51 UTHR

5.59+1.12%

United Therapeutics Corporation$502.70 ONC

7.32+2.11%

BeOne Medicines AG$353.83 KRYS

-6.97-2.01%

Krystal Biotech, Inc.$340.03 PRAX

-4.03-1.20%

Praxis Precision Medicines, Inc.$330.55 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 LGND

-3.82-1.34%

Ligand Pharmaceuticals Incorporated$280.65

Company Overview

Aktis Oncology, Inc. (NASDAQ:AKTS) closed at $23.17 USD, losing -$0.13 (-0.56%) from the previous close of $23.30. The stock is currently mid-range between its 52-week high and low $14.72 and $34.19. With a market capitalization of about $1.24 billion, Aktis Oncology, Inc. is classified as a small-cap and shows lower-than-market volatility (beta ~0.45). Key stats such as the average daily volume over the past year has been around 394.41 thousand shares, in line with its 52-week average. Headquartered in Boston, MA, Aktis Oncology, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Matthew Roden, the company employs approximately 79 people and listed since January 09, 2026. Aktis Oncology, Inc. is a clinical-stage biotechnology firm dedicated to advancing targeted radiopharmaceutical therapies for cancer treatment.

Technical Performance

Short-term trend indicators are mixed aligned (SMA20 2.45%, SMA50 -1.31%, SMA200 -1.31%). The stock’s 14-day RSI is 48.45 (neutral), while the ATR of 1.69 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -32.68% below its high and over 16.85% above its low. Average 10-day trading volume of 353.31 thousand shares is below the 3-month average of 393.72 thousand, indicating normal recent market interest.

Valuation Metrics

Aktis Oncology, Inc. trades at a P/E ratio of -21.99, slightly below the S&P 500 average, with a price-to-sales ratio of 122.55 and a price-to-book ratio of 2.63 suggesting the stock is closer to book value. The P/FCF stands at -14.58, also below market averages.

Dividend & Fair Value

Aktis Oncology, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.50. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

The latest quarter delivered EPS of -$0.44. The next quarter is forecast at -$21.59. Next year's EPS is expected at $42.78. Analyst sentiment is bullish. Analyst rating data shows there are 6 Strong Buy ratings, 3 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $40.00 to $30.00. The high target offers 72.64% upside. The low target suggests 29.48% downside. The mean target is $34.78. This offers 50.11% upside. Aktis Oncology, Inc. earnings surprise history is a mixed track record. The quarter that ended August 13, 2026, missed forecasts by 0.0%. The prior quarter beat by 22.58%. Over the last six quarters, Apple has recorded several small beats. These include 90.91% in September 25, 2024.

Shareholding & Insider Activity

Aktis Oncology, Inc. has 53.75 million shares outstanding. The public float is 28.59 million shares, elevated short interest at 19.64% of float. This equals 3.18 million shares. The short ratio is 11.59 days. Institutional investors hold 86.52% of the float. Insiders own 14.14%. Shealy Jeffrey B. holds 2.22 million shares, McMahon Jeffrey has 484.34 thousand shares and Geiss Arthur has 415.92 thousand shares.

Financial & Profitability Overview

Over the trailing twelve months, Aktis Oncology generated $27.38M in revenue, or $0.31 per share. Gross margin was -2.52%, operating margin -401.66%, and net profit margin -613.31%. Returns are negative, with ROA at -240.82% and ROE at 294.16%.
On valuation metrics, Aktis Oncology trades at a P/E of -21.99, P/S of 122.55 and P/B of 2.63. The current ratio is 16.33 and quick ratio is 16.33. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -520.43 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.02, supported by a cash flow-to-debt ratio of -6.70.

Quarterly Financial Highlights

For the quarter ended Jun 30, 2024, Aktis Oncology posted revenue of $27.38M, down slightly from $27.12M in the prior quarter. Gross profit was - $689.00K (margin -2.52%). Operating income was - $109.99M (margin -401.7%). Net income was- $167.95M (EPS - $1.89).
The company ended the quarter with $24.45M in cash and short-term investments, a total debt of $52.86M, and net debt of $28.42M. Total assets were $69.74M, with equity of - $57.09M. Financials further reflected weakness, with operating cash flow of - $40.35M, free cash flow of - $46.34M, and capital expenditures of - $5.99M.

Price Forecast & Outlook

Our AI price prediction model suggests that Aktis Oncology, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -3.93%, with price expected at $22.26 by September 28, 2026, within a range of $21.31 to $23.22 3-Month Outlook: Projected rise of 542.43%, reaching $148.85 by December 11, 2026, with a range of $148.63 to $149.12. 1-Year Outlook: Projected gain of 31.16%, with price at $30.39 by September 14, 2027, within a range of $28.51 to $32.91.

Key Takeaways

Aktis Oncology, Inc. (NASDAQ:AKTS) shares are down -16.21% year-to-date currently trading near 52-week highs band. Valuation shows Aktis Oncology, Inc. trading at a premium to the broader market with a P/E of -21.99. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $18.23, suggesting -21.32% downside. Our AI forecast model points to short-term weakness (-3.93% over two weeks), a medium-term rise (542.43% over three months), and a longer-term gain (31.16% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Aktis Oncology, Inc. (AKTS) stock price?

Aktis Oncology, Inc. (NASDAQ: AKTS) stock price is $23.17 in the last trading session. During the trading session, AKTS stock reached the peak price of $23.71 while $22.79 was the lowest point it dropped to. The percentage change in AKTS stock occurred in the recent session was -0.56% while the dollar amount for the price change in AKTS stock was - $0.13.

AKTS's industry and sector of operation?

The NASDAQ listed AKTS is part of Biotechnology industry that operates in the broader Healthcare sector. Aktis Oncology, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of AKTS?

Mr. Andrew Wright
Gen. Counsel & Corporation Sec.
Mr. Jeffrey B. Shealy
Founder, Pres, Chief Executive Officer & Director
Mr. Kenneth E. Boller
Chief Financial Officer & Corporation Controller
Mr. Kamran Cheema
Chief Product Officer
Mr. David M. Aichele
Executive Vice President of Bus. Devel.
Ms. Mary Winters
Executive Vice President of Fab & Corporation Operations
Mr. Thomas Andrew Sepenzis
Vice President of Corporation Devel. & IR

How AKTS did perform over past 52-week?

AKTS's closing price is 57.41% higher than its 52-week low of $14.72 where as its distance from 52-week high of $34.19 is -32.23%.

How many employees does AKTS have?

Number of AKTS employees currently stands at 79.

Link for AKTS official website?

Official Website of AKTS is: https://www.aktisoncology.com

How do I contact AKTS?

AKTS could be contacted at phone 617 461 4023 and can also be accessed through its website. AKTS operates from 17 Drydock Avenue, Boston, MA 02210, United States.

How many shares of AKTS are traded daily?

AKTS stock volume for the day was 330.07K shares. The average number of AKTS shares traded daily for last 3 months was 394.41K.

What is the market cap of AKTS currently?

The market value of AKTS currently stands at $1.24B with its latest stock price at $23.17 and 53.4M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	79
Beta	0.45
Sales or Revenue	$27.38M
5Y Sales Change%	6.386%
Fiscal Year Ends	June
Sector	Healthcare
Industry	Biotechnology

AKTS Company Profile and Key Details

Aktis Oncology

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Financial & Profitability Overview

Quarterly Financial Highlights

Dividend & Fair Value

Earnings & Analyst Outlook

Technical Performance

Shareholding & Insider Activity

Company Overview

Valuation Metrics

Price Forecast & Outlook

Key Takeaways